Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system

Khakpai, Fatemeh; Ebrahimi-Ghiri, Mohaddeseh; Alijanpour, Sakineh; Zarrindast, Mohammad‐Reza

doi:10.1016/j.biopha.2019.108717

Cited by 32 publications

(14 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Animal models of depression show a reduction of CB2Rs in the striatum, midbrain, and hippocampus (Garcia- Gutierrez et al, 2010). Several studies have reported that AM630 resulted in an antidepressant-like effect (Khakpai et al, 2019;Kruk-Slomka et al, 2015). Interestingly, chronic administration of AM630 blocked or significantly reduced signs of depressive-like behavior and CB2R and BDNF loss in the hippocampus of mice exposed to chronic mild stress (Garcia- Gutierrez et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

“…However, centrally acting antagonists of CB1R also produce adverse effects like depression and anxiety (Nguyen et al, 2019). Nevertheless, some studies have reported an antidepressant property following systemic administration of AM251 in mice (Khakpai et al, 2019; Shearman et al, 2003). In line with our observations, Umathe et al found no alteration in the performance of mice in the FST following I.C.V.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

URB597 abrogates anxiogenic and depressive behaviors in the methamphetamine-withdrawal mice: Role of the cannabinoid receptor type 1, cannabinoid receptor type 2, and transient receptor potential vanilloid 1 channels

2020

Self Cite

View full text Add to dashboard Cite

Background: Methamphetamine is an addictive stimulant that possesses toxicity in the brain when taken repeatedly or at higher doses. Methamphetamine neurotoxicity is associated with numerous forms of mental impairment, including depression and anxiety. Evidence has also demonstrated that the endocannabinoid system is involved in the regulation of anxiety and depression. Aims: This study was designed to determine the involvement of the endocannabinoid system in anxiety- and depression-related behaviors in methamphetamine-withdrawal male NMRI mice. Methods: The elevated plus maze and forced swim test were used to assess the level of anxiety and depression. Results: We found that methamphetamine (30 mg/kg, intraperitoneal) evoked depressive- and anxiogenic-like effects at 3 days post-administration. Injection of URB597 (5–10 ng/mouse, intracerebroventricular), 10 min before the test, prevented the emotional deficits induced by methamphetamine withdrawal. Moreover, the cannabinoid receptor type 1 antagonist AM251 (1 μg/mouse) or cannabinoid receptor type 2 antagonist AM630 (5 and 10 μg/mouse) suppressed the antidepressant activity in the methamphetamine-withdrawal mice treated with URB597. The transient receptor potential vanilloid 1 antagonist capsazepine (25 μg/mouse) prevented while capsazepine (100 μg/mouse) potentiated the antidepressant efficacy in the methamphetamine-withdrawal mice treated with URB597. The higher dose of AM630 and two higher doses of capsazepine had antidepressant efficacy, by themselves. Furthermore, capsazepine (50 μg/mouse) increased locomotion in the methamphetamine-withdrawal mice treated with URB597. Conclusions: The results suggest that URB597 has a potential for preventing methamphetamine withdrawal-evoked anxiety and depression. Cannabinoid type 1 receptors, cannabinoid type 2 receptors and transient receptor potential vanilloid 1 differently affect depression-related behaviors in methamphetamine-withdrawal mice treated with URB597.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

URB597 abrogates anxiogenic and depressive behaviors in the methamphetamine-withdrawal mice: Role of the cannabinoid receptor type 1, cannabinoid receptor type 2, and transient receptor potential vanilloid 1 channels

2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Interestingly, a study on mice showed that the administration of either CB1 agonist ACPA (1 mg/kg), CB1 antagonist AM251 (1 mg/kg), CB2 agonist GP1a (2 mg/kg), or CB2 antagonist AM630 (0.5 mg/kg) had anti-depressive effects. Additionally, the co-administration of a small, ineffective dose of ketamine (5 mg/kg) with CB1 or CB2 antagonist led to antidepressant action [123]. Antidepressant effects of AM251 (10 mg/kg) had been shown before in rodent models [124].…”

Section: Depressionmentioning

confidence: 95%

A Guide to Targeting the Endocannabinoid System in Drug Design

Stasiulewicz

Znajdek

Grudzień

et al. 2020

IJMS

View full text Add to dashboard Cite

The endocannabinoid system (ECS) is one of the most crucial systems in the human organism, exhibiting multi-purpose regulatory character. It is engaged in a vast array of physiological processes, including nociception, mood regulation, cognitive functions, neurogenesis and neuroprotection, appetite, lipid metabolism, as well as cell growth and proliferation. Thus, ECS proteins, including cannabinoid receptors and their endogenous ligands’ synthesizing and degrading enzymes, are promising therapeutic targets. Their modulation has been employed in or extensively studied as a treatment of multiple diseases. However, due to a complex nature of ECS and its crosstalk with other biological systems, the development of novel drugs turned out to be a challenging task. In this review, we summarize potential therapeutic applications for ECS-targeting drugs, especially focusing on promising synthetic compounds and preclinical studies. We put emphasis on modulation of specific proteins of ECS in different pathophysiological areas. In addition, we stress possible difficulties and risks and highlight proposed solutions. By presenting this review, we point out information pivotal in the spotlight of ECS-targeting drug design, as well as provide an overview of the current state of knowledge on ECS-related pharmacodynamics and show possible directions for needed research.

show abstract

“…Therefore, the patent provided a method for modulating this type of antibody for the treatment of immune system-related conditions such as allergy, hay fever and the like. Biological literature concerning Gp-1a pointed out the relevance of such a compound as a useful pharmacological tool to ascertain in more detail the role of CB 2 receptors in physiopathological conditions [32][33][34][35][36]. Furthermore, the pharmacological relevance of 1,4-dihydroindeno(1,2-c)pyrazole-based I compounds emerged also from the significant anti-nociceptive activity of the potent and selective CB 2 agonist IDhX, namely NESS400, in Spared Nerve Injury (SNI) neuropathic mice, by alleviating both mechanical allodynia and thermal hyperalgesia [37].…”

Section: (55)-condensed Pyrazole Derivativesmentioning

confidence: 99%

Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB1/CB2 Receptor Interaction

et al. 2021

View full text Add to dashboard Cite

Cannabinoids comprise different classes of compounds, which aroused interest in recent years because of their several pharmacological properties. Such properties include analgesic activity, bodyweight reduction, the antiemetic effect, the reduction of intraocular pressure and many others, which appear correlated to the affinity of cannabinoids towards CB1 and/or CB2 receptors. Within the search aiming to identify novel chemical scaffolds for cannabinoid receptor interaction, the CB1 antagonist/inverse agonist pyrazole-based derivative rimonabant has been modified, giving rise to several tricyclic pyrazole-based compounds, most of which endowed of high affinity and selectivity for CB1 or CB2 receptors. The aim of this review is to present the synthesis and summarize the SAR study of such tricyclic pyrazole-based compounds, evidencing, for some derivatives, their potential in the treatment of neuropathic pain, obesity or in the management of glaucoma.

show abstract

Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system

Cited by 32 publications

References 43 publications

URB597 abrogates anxiogenic and depressive behaviors in the methamphetamine-withdrawal mice: Role of the cannabinoid receptor type 1, cannabinoid receptor type 2, and transient receptor potential vanilloid 1 channels

URB597 abrogates anxiogenic and depressive behaviors in the methamphetamine-withdrawal mice: Role of the cannabinoid receptor type 1, cannabinoid receptor type 2, and transient receptor potential vanilloid 1 channels

A Guide to Targeting the Endocannabinoid System in Drug Design

Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB1/CB2 Receptor Interaction

Contact Info

Product

Resources

About